Cargando…

Profile of veliparib and its potential in the treatment of solid tumors

Inhibition of poly(ADP-ribose) polymerase (PARP) is an attractive therapeutic strategy because of the importance of this pathway in restoring DNA damage. Small-molecule inhibitors of PARP appear most effective when used to treat tumors with underlying defects in DNA repair, or when combined with DNA...

Descripción completa

Detalles Bibliográficos
Autor principal:	Wagner, Lars M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524591/ https://www.ncbi.nlm.nih.gov/pubmed/26251615 http://dx.doi.org/10.2147/OTT.S69935

Ejemplares similares

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
por: Werner, Theresa L., et al.
Publicado: (2018)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Profile of farletuzumab and its potential in the treatment of solid tumors
por: Sato, Seiya, et al.
Publicado: (2016)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Profile of panobinostat and its potential for treatment in solid tumors: an update
por: Anne, Madhurima, et al.
Publicado: (2013)

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
por: Schmidtova, Silvia, et al.
Publicado: (2022)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
por: Munasinghe, Wijith, et al.
Publicado: (2016)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
por: Berlin, Jordan, et al.
Publicado: (2018)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
por: Cecchini, Michael, et al.
Publicado: (2023)

Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials
por: Daei Sorkhabi, Amin, et al.
Publicado: (2023)

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma
por: Wang, Jing, et al.
Publicado: (2022)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
por: Bellantoni, Andrew J., et al.
Publicado: (2021)

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
por: Wagner, Lars M, et al.
Publicado: (2017)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
por: Owonikoko, Taofeek K, et al.
Publicado: (2014)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
por: Stringer-Reasor, Erica M., et al.
Publicado: (2021)

Profile of nintedanib in the treatment of solid tumors: the evidence to date
por: Awasthi, Niranjan, et al.
Publicado: (2015)

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study
por: You, Benoit, et al.
Publicado: (2023)

In Vitro and In Vivo Efficacy of DNA Damage Repair Inhibitor Veliparib in Combination with Artesunate against Echinococcus granulosus
por: Li, Y. F., et al.
Publicado: (2020)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
por: Kota, Karthik, et al.
Publicado: (2017)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

MDB-36. SONIDEGIB, GANT61, AND VELIPARIB TREATMENT BOTH ALONE AND IN COMBINATION INCREASES RADIATION SENSITIVITY IN PEDIATRIC SONIC HEDGEHOG MEDULLOBLASTOMA
por: Price, Laura, et al.
Publicado: (2023)

Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib
por: Al-Ansari, Sali, et al.
Publicado: (2022)

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial
por: Aghajanian, Carol, et al.
Publicado: (2022)

Potential of epigenetic therapies in the management of solid tumors
por: Valdespino, Victor, et al.
Publicado: (2015)

Das BRCA-like-Mammakarzinom profitiert von Cisplatin plus Veliparib; Ergebnisse der S1416-Phase-II-Studie
por: Hintelmann, Katharina, et al.
Publicado: (2023)

Efficacy and safety of veliparib combined with traditional chemotherapy for treating patients with lung cancer: a comprehensive review and meta-analysis
por: Zhao, Guanhua, et al.
Publicado: (2023)

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
por: Tuli, R., et al.
Publicado: (2019)

Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors
por: Davidson, Cole D., et al.
Publicado: (2021)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Profile of lebrikizumab and its potential in the treatment of asthma
por: Maselli, Diego Jose, et al.
Publicado: (2015)

Profile of brivaracetam and its potential in the treatment of epilepsy
por: Ferlazzo, Edoardo, et al.
Publicado: (2015)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Profile of minocycline and its potential in the treatment of schizophrenia
por: Zhang, Lulu, et al.
Publicado: (2014)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Profile of adalimumab and its potential in the treatment of uveitis
por: Balevic, Stephen J, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7tk3cv9qnqa7bme2dlh9s7dlfk